The fascinating scientific history of phage therapy has been documented in numerous publications. In this study, however, we focus on an angle of the story that hitherto has remained relatively neglected, namely, phage therapy treatments, and the protagonists that conducted these in Mandatory-Palestine and subsequently the state of Israel, as part of a global trend. We complete the story by describing efforts in the new era of phage therapy in present-day Israel.
Get full access to this article
View all access options for this article.
References
1.
OlitzkiAL. Bacteriophages and its use as therapy for rod Bohrdom. Harefuah. 1929; 3(2):7–9.
2.
Nir-PazR, GelmanD, KhouriA, et al.Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis. 2019; 69(11):2015–2018.
3.
AbedonST, Thomas-AbedonC, ThomasA, et al.Bacteriophage prehistory: Is or is not Hankin, 1896, a phage reference?. Bacteriophage. 2011; 1(3):174–178.
4.
D'HerelleF. On an invisible microbe antagonistic toward dysenteric bacilli: Brief note by Mr. F. D'Herelle, presented by Mr. Roux. 1917. Res Microbiol. 2007; 158(7):553–554.
5.
ChanishviliN. Phage therapy-history from Twort and d'Herelle through Soviet experience to current approaches. In: ŁobockaM, SzybalskiW, eds. Advances in Virus Research, vol. 83. US: Academic Press Inc., 2012:3–40.
6.
CipollaroAC, SheplarAE. Therapeutic uses of bacteriophage in the pyodermias. Arch Derm Syphilol. 1932; 25(2):280–293.
7.
TownAE, FrisbeeFC. Bacteriophage in ophthalmology: A preliminary report. Arch Ophthalmol. 1932; 8(5):683–689.
8.
KutateladzeM, AdamiaR. Phage therapy experience at the Eliava Institute. Médecine Mal Infect. 2008; 38(8):426–430.
9.
Nissim LevyYL. On Title Page Verso: Physicians of the Holy Land, 1799–1948. Israel: Itay Bahur Publishing, 2017.
10.
KatvanE. ‘That was the beginning’: The professionalization and Americanization of dentistry in pre-state Israel. J Hist Dent. 2010; 58(3):147–156.
11.
ShvartsS, FalchukN, Mor-YosefS, et al.Hadassah for the Health of the People: The Health Education Mission of Hadassah: The Ameican Zionist Women in the Holy Land. Dekel Academic Press, 2012.
12.
ShvartsS, BrownTM, HolimK. Dr. Isaac Max Rubinow, and the American Zionist Medical Unit's experiment to establish health care services in Palestine, 1918–1923. Bull Hist Med. 1998; 72(1):28–46.
13.
AnsonO, SovalYT. The main thing is health: social structure and health in Israel. Jerusalem: Magnes Press of the Hebrew University, 2000.
14.
KliglerIJ. Memorandum on the Activities of the Department of Hygiene of the 1926–1928. The Hebrew University Archive, 1928.
15.
NiderlandD. The Influence of German-Immigrant Physicians on the Development of Medicine in Israel (1933–1948). An M.Sc thesis of Doron Niderland with the instruction of Moshe Zimmermann from the Hebrew University, Jerusalem, Israel, 1983.
16.
KirschDN. Hebrew researchers dream in German: Scientists from Germany at the Hebrew University during the Yishuv period. Galileo, 2008; 117(1):17–20.
17.
GreenbergZ, AlexanderA. Israel Jacob Kligler: The story of “A little big man.”Korot. 2011; 21:2011–2012.
18.
HajnaAA. Triple-sugar iron agar medium for the identification of the intestinal group of bacteria. J Bacteriol. 1945; 49(5):516–517.
19.
LevyN, LevyY. Rofeha shel Erets-Yisrael 1948–1799 = Physicians of the Holy Land, 1799–1948. Israel: Itay Bahur Publishing, 2012.
20.
GrossowiczN. To Prof. AL Olitzky on His 60th Birthday. Harefuah. 1958; 54(11):296–301.
21.
OlitzkiL. Contribution of bacteriologists for the control of infectious diseases in Palestine. Harofe Haivri Heb Med J. 1947; 2:174–180.
22.
KliglerIJ, OlitzkiL. Studies on protein-free suspensions of viruses. V: Further observations on the nature and antigenic properties of a highly purified phage. Br J Exp Pathol. 1934; 15(1):14.
23.
KliglerIJ, OlitzkiL. Studies on protein-free suspensions of viruses. III.—The resistance to heat and disinfectants of protein-free eluates of a bacteriophage and Fowl-pox virus. Br J Exp Pathol. 1931; 12(6):393.
24.
KliglerIJ, OlitzkiL, AschnerM. Studies on protein-free suspensions of viruses. II.—Cataphoresis experiments with protein-free suspensions of a bacteriophage and Fowl-pox virus. Br J Exp Pathol. 1931; 12(3):178.
25.
KliglerIJ, OlitzkiL. Studies on protein-free suspensions of viruses. I.—The adsorption and elution of bacteriophage and Fowl-pox virus. Br J Exp Pathol. 1931; 12(3):172.
26.
KliglerIJ, OlitzkiL. Purification of phage by adsorption and elution. Proc Soc Exp Biol Med. 1933; 30(9):1365–1367.
27.
SandholzerLA, MannMM, BerryGP. Determination of ultra-violet light absorption by certain bacteriophages. Science (80−.). 1937; 86(2222):104–105.
28.
ŻaczekM, Weber-DąbrowskaB, MiędzybrodzkiR, et al.Phage therapy in Poland—A Centennial journey to the first ethically approved treatment facility in Europe. Front Microbiol. 2020; 11:1056.
29.
WeiszGM. Remembering Jewish physicians. Isr Med Assoc J. 2015; 17(4):203–205.
30.
GrzybowskiA, ŻaczekM, GórskiA, et al.Bronisława Fejgin (1883–1943): Forgotten important contributor to international microbiology and phage therapy. Antibiotics. 2021; 10(11):1353.
31.
FejginB. On the sudden variations of Proteus HX19 occurring under the influence of the anti-HX19 lytic agent and their relationship with the strains isolated from guinea pigs infected with the passage virus of exanthematous typhus. CR Soc Biol. 1924; 90:1106–1108.
32.
AbdelsattarAS, DawooudA, RezkN, et al.How to train your phage: The recent efforts in phage training. Biologics. 2021; 1(2):70–88.
33.
BorinJM, AvraniS, BarrickJE, et al.Coevolutionary phage training leads to greater bacterial suppression and delays the evolution of phage resistance. Proc Natl Acad Sci USA. 2021; 118(23):e2104592118.
34.
OlitzkiL. In memoriam of Israel Kligler. Harefuah. 1944; 27:185–189.
35.
KliglerIJ, OleinikE. Inactivation of phage by aldehydes and aldoses and subsequent reactivation. J Immunol. 1943; 47(4):325–333.
36.
KliglerIJ, OleinikE, CzazkesI. Improved technic for isolation of dysentery bacteria from stools by formaldehyde inactivation of bacteriophage. Am J Public Health Nations Health. 1943; 33(6):682–684.
37.
OlitzkiAL, ShelubskyM, StraussW. Typing of typhoid bacteria and its value in epidemiological research in Palestine. Harefuah. 1948; 34(9):105–107.
38.
OlitzkiL. Mucin as a resistance-lowering substance. Bacteriol Rev. 1948; 12(2):149–172.
Sheffer-LeviS, RimonA, LererV, et al.Antibiotic susceptibility of Cutibacterium acnes strains isolated from Israeli Acne Patients. Acta Derm Venereol. 2020; 100(17): adv00295.
45.
SufianSM. Healing the Land and the Nation: Malaria and the Zionist Project in Mandatory-Palestine, 1920–1947. New York University, 1999.
46.
SufianS. Colonial malariology, medical borders, and sharing scientific knowledge in Mandatory-Palestine. Sci Context. 2006; 19(3):381–400.
47.
EatonMD, Bayne-JonesS. Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections. J Am Med Assoc. 1934; 103(23):1769–1776.
MyelnikovD. Creature features: The lively narratives of bacteriophages in Soviet biology and medicine. Notes Rec R Soc J Hist Sci. 2020; 74(4):579–597.
50.
DugatkinLA, TrutL, TrutLN. How to Tame a Fox (and Build a Dog): Visionary Scientists and a Siberian Tale of Jump-Started Evolution. University of Chicago Press, 2017.
51.
SalmondGPC, FineranPC. A century of the phage: Past, present and future. Nat Rev Microbiol. 2015; 13(12):777–786.
52.
JacobF, MonodJ. Genetic regulatory mechanisms in the synthesis of proteins. J Mol Biol. 1961; 3(3):318–356.
SegalE. Healing by Infection (Bacteriophages and Their Actions). Herut, 1950.
56.
OlitzkiAL. Healing byBacteriophages. Davar, 1958.
57.
GelmanD, YerushalmyO, Ben-PoratS, et al.Clinical phage microbiology: A suggested framework and recommendations for the in-vitro matching steps of phage therapy. Lancet Microbe. 2021; 2(10):e555–e563.
58.
Ben-GurionR. Photoreactivation and cysteine reversion of lysogenic induction. J Mol Biol. 1964; 9(3):619–623.
59.
Ben-GurionR. The production of phage in induced lysogenic and in infected sensitive bacteria. Virology. 1963; 20(2):288–291.
60.
ShemerM. Genetical Mistakes Might Be Beneficial. Davar, the daily news paper of the workers of the Land of Israel, 1969.
61.
BoraA. Hebrew University Scientists in Jerusalem Discovered: Substances That Inhibit the Culture of Bacteria and Viruses. LaMerhav, a Hebrew language daily newspaper published by the Ahdut HaAvoda party, 1969.
62.
HareuveniM. The Study of the Discovery of the Secret of Life (About Dr. Lurie who won the Nobel Prize); Lamerhav, 1969.
63.
ShomronB. Centropoga (On Centrifuge and Phage Insulation). The Cattle, 1963.
64.
Genetic Therapy Breakthrough. Davar, the daily newspaper of the workers of the Land of Israel, 1971.
65.
AltuviaS, Locker-GiladiH, KobyS, et al.RNase III stimulates the translation of the cIII gene of bacteriophage lambda. Proc Natl Acad Sci USA. 1987; 84(18):6511–6515.
66.
OppenheimAB, KobilerO, StavansJ, et al.Switches in bacteriophage lambda development. Annu Rev Genet. 2005; 39:409–429.
67.
RokneyA, KobilerO, AmirA, et al.Host responses influence on the induction of lambda prophage. Mol Microbiol. 2008; 68(1):29–36.
68.
AdhyaSL, CourtDL, FriedmanDI, et al.Amos Oppenheim (31 October 1934 to 24 September 2006). Mol Microbiol. 2008; 67(4):685–686.
69.
KuhnJ, SuissaM, WyseJ, et al.Detection of bacteria using foreign DNA: The development of a bacteriophage reagent for Salmonella. Int J Food Microbiol. 2002; 74(3):229–238.
70.
RossoliniGM, ArenaF, PecileP, et al.Update on the antibiotic resistance crisis. Curr Opin Pharmacol. 2014; 18:56–60.
71.
MurrayCJL, IkutaKS, ShararaF, et al., Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399:629–655.
72.
RosiniR, NicchiS, PizzaM, et al.Vaccines against antimicrobial resistance. Front Immunol. 2020; 11:1048.
73.
DjebaraS, MaussenC, De VosD, et al.Processing phage therapy requests in a Brussels military hospital: Lessons identified. Viruses. 2019; 11(3):265.
74.
LinRCY, SacherJC, CeyssensP-J, et al.Phage biobank: Present challenges and future perspectives. Curr Opin Biotechnol. 2021; 68:221–230.
75.
AslamS, LampleyE, WootenD, et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. In: Baddley JW, Spec A, eds. Open Forum Infectious Diseases, vol. 7. Oxford University Press US, 2020:ofaa389.
76.
FerryT, KolendaC, BriotT, et al.Implementation of a complex bone and joint infection phage therapy centre in France: Lessons to be learned after 4 years' experience. Clin Microbiol Infect. 2022; 28(1):145–146.
77.
JaultP, LeclercT, JennesS, et al.efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019; 19(1):35–45.
78.
SarkerSA, SultanaS, ReutelerG, et al.Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: A randomized trial in children from Bangladesh. EBioMedicine. 2016; 4:124–137.
79.
WrightA, HawkinsCH, ÄnggårdEE, et al.A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009; 34(4):349–357.
80.
FurfaroLL, PayneMS, ChangBJ. Bacteriophage therapy: Clinical trials and regulatory hurdles. Front Cell Infect Microbiol. 2018; 8:376.
81.
SchooleyRT, BiswasB, GillJJ, et al.Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017; 61(10):e00954-17.
82.
GraifN, AbozaidS, PeretzA. Trends in distribution and antibiotic resistance of bacteria isolated from urine cultures of children in Northern Israel between 2010 and 2017. Microb Drug Resist. 2020; 26(11):1342–1349.
CohenY, Joseph PollockF, RosenbergE, et al.Phage therapy treatment of the coral pathogen Vibrio coralliilyticus. Microbiologyopen. 2013; 2(1):64–74.
85.
AtadI, ZvuloniA, LoyaY, et al.Phage therapy of the white plague-like disease of Favia favus in the Red Sea. Coral Reefs. 2012; 31(3):665–670.
86.
MosesS, AftalionM, MamroudE, et al.Reporter-phage-based detection and antibiotic susceptibility testing of Yersinia pestis for a rapid plague outbreak response. Microorganisms. 2021; 9(6):1278.
87.
MosesS, VagimaY, TidharA, et al.Characterization of Yersinia pestis phage lytic activity in human whole blood for the selection of efficient therapeutic phages. Viruses. 2021; 13(1):89.
88.
VagimaY, GurD, AftalionM, et al.Phage therapy potentiates second-line antibiotic treatment against pneumonic plague. Viruses. 2022; 14(4):688.
89.
KhatamiA, LinRCY, Petrovic-FabijanA, et al.Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child. EMBO Mol Med. 2021; 13(9):e13936.
90.
Alkalay-OrenS, YerushalmyO, AdlerK, et al.Complete genome sequence of Pseudomonas aeruginosa bacteriophage PASA16, used in multiple phage therapy treatments globally. Microbiol Resour Announc. 2022; 11(4):e00092-22.
91.
YerushalmyO, KhalifaL, GoldN, et al.The Israeli phage bank (IPB). Antibiotics. 2020; 9(5):269.
92.
PaulK, MerabishviliM, HazanR, et al.Bacteriophage rescue therapy of a vancomycin-resistant Enterococcus faecium infection in a one-year-old child following a third liver transplantation. Viruses. 2021; 13(9):1785.
93.
YerushalmyO, Coppenhagen-GlazerS, Nir-PazR, et al.Complete genome sequences of two Klebsiella pneumoniae phages isolated as part of an international effort. Microbiol. Resour. Announc. 2019; 8(38):e00843-19.
94.
SmithM. Salt in My Soul: An Unfinished Life. Random House: New York, NY; 2021.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
